CHEK2 and acute lymphoblastic leukemia: Our group has recently showed the effectiveness of PF-0477736, a Chk1/Chk2 inhibitor, in single agent on a panel of different B-/T-ALL cell lines and on primary leukemic cells isolated from adult B-ALL patients.